Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| NASH Market (Drugs) to see 25.56% CAGR During 2020 - 2030 | ||
| By: PR Newswire Association LLC. - 06 May 2016 | Back to overview list |
|
PUNE, India, May 6, 2016 /PRNewswire/ -- Global NASH market report says progressive numbers of liver disorders along with rise in obesity will fuel the demand for NASH (non-alcoholic steatohepatitis) drugs in the coming few years. The NASH Market is growing at a moderate rate over last five years on account of rising number of obesity among young population. NASH (non-alcoholic steatohepatitis) is a large, un-tapped market with no FDA approved therapeutics. Antioxidants, anti-diabetic medications, anti-obesity medications and antihyper Lipidemics are some of the off-label products currently used by NASH patients. Moreover, increase in number of patients suffering from fat in liver disorder is further anticipated to boost the Global NASH market in the coming years. Complete report NASH (Non-Alcoholics Steatohepatitis) Market spread across 112 pages, analyzing 4 major companies and provides 43 data figures is now available at http://www.reportsnreports.com/reports/447019-global-nash-non-alcoholics-steatohepatitis-market-trends-opportunities-and-forecasts-2015-2030-by-region-by-drugs-off-label-special-treatment-drugs-aramachol-clinical-pipeline-gr-md-02-gft-505-market-.html. According to research report, "Global NASH (Non -Alcoholics Steatohepatitis) Market: Trends, Opportunities and Forecasts (2015-2030) - (By Region, By Drugs - Off Label & Special Treatment, Aramachol, Clinical Pipeline, GR-MD-02, GFT 505 Market)", global non-alcoholic steatohepatitis drug specific market is estimated to start growing by 2020 at a CAGR of 25.56% during 2020-2030, due to the projected product launches in 2020. Surge in cycles of clinical trials and their success rate has improved the probability of industries receiving commercial approval for NASH therapeutics by the end of 2020. Additionally, the absence of efficient diagnostic technologies acts as a major hurdle for the research of NASH therapeutics. Moreover increase in awareness among people regarding this disease may reduce propelling growth of this degenerative disorder. In addition, expansion plans and investments are anticipated to boost the Global NASH Disease Market during 2015-20. In terms of segmentation, market is categorized By off Label Drug, By Speciality Drug, By NAFLD and By Patient. Although, North America Region is anticipated to lead the revenue contribution to the Global NASH Market, Europe is also expected to witness a higher growth rate till 2020. Nevertheless, the emergence of novel biomarker technologies and improvements in liver biopsy technologies are expected to bring about an evolution in the diagnosis of NASH and other fatty liver diseases. Despite of these challenges, certain key players such as Galmed Pharmaceuticals, Gilead Sciences, Novo Nordisk, Genfit, Intercept and Galectin Therapeutics are conducting extensive research on NASH therapeutics and are receiving positive results from clinical trials. But, the low diagnosis rates, low prescription rates and low treatment seeking rates continue to pose significant challenges for these emerging players. The United States, which has the highest number of research initiatives concerning NASH, holds nearly half of the global market share. The chief reason behind this growth is the high prevalence of diabetes and obesity and the growing number of people suffering with these conditions. The US has the highest number cases of NASH and other non-alcoholic fatty liver diseases. Order a copy of this NASH market report at http://www.reportsnreports.com/purchase.aspx?name=447019 . On a related note, another research titled Rising Stars Outlook 2016: New Emergence of Potential Tx & Dx Options could transform the Current Landscape for Liver Diseases (NASH) says potential market is gigantic with analysts predicting north of $35bn by 2025! Many small players are currently developing drugs on their own and with such a large unmet need, market potential and disease heterogeneity, this research expects many Giants to join this race and thus, more Licensing deals/ M&A activity may be visible on the horizon! In light of recent developments in NASH, this report covers few in-depth coverage of companies which either target early-stage NASH, late-stage NASH, or large pts pool-NAFLD in our Outlook this year. Companies mentioned in this report include Conatus Pharmaceuticals (CNAT), Galectin Therapeutics (GALT), Galmed Pharmaceuticals (GLMD), Genfit SA (GNFT), Intercept Pharmaceuticals (ICPT) and Tobira Therapeutics (TBRA). Read more at http://www.reportsnreports.com/reports/516281-rising-stars-outlook-2016-new-emergence-of-potential-tx-dx-options-could-transform-the-current-landscape-for-liver-diseases-nash-.html . Explore other new reports on pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/. About Us: ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more. Connect With Us on: Facebook: https://www.facebook.com/ReportsnReports/ LinkedIn: https://www.linkedin.com/company/reportsnreports Twitter: https: //twitter.com/marketsreports G+ / Google Plus: https://plus.google.com/111656568937629536321/posts RSS/Feeds: http: //http://www.reportsnreports.com/feed/l-latestreports.xml
|
||
|
|
||
 | Back to overview list | |